odm-104
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01840423)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Catechol O-methyltransferaseINHIBITOR
COMT inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- odm-104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04571996 | Phase 1 | Oct 29, 2020 | Orion Corporation |
| NCT03140956 | Phase 1 | Apr 19, 2017 | Orion Corporation |
| NCT03055936 | Phase 1 | Feb 21, 2017 | Nuvisan Pharma Services, Orion Corporation |
| NCT01840423 | Phase 1 | May 1, 2013 | Orion Corporation, Parexel |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Orion Corporation | For profit | 4 | 4 | 1 | 2013 |
| Nuvisan Pharma Services | For profit | 1 | 0 | 1 | 2017 |
| Parexel | For profit | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1